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a b s t r a c tMammalian target of rapamycin (mTOR) inhibitors are used as potent immunosuppressive agents in solid-
organ transplant recipients (everolimus and sirolimus) and as antineoplastic therapies for various cancers (eg,
advanced renal cell carcinoma; everolimus, temsirolimus, ridaforolimus). Relevant literature, obtained from
speciﬁc PubMed searches, was reviewed to evaluate the incidence and mechanistic features of speciﬁc
adverse events (AEs) associated with mTOR inhibitor treatment, and to present strategies to effectively
manage these events. The AEs examined in this review include stomatitis and other cutaneous AEs, wound-
healing complications (eg, lymphocele, incisional hernia), diabetes/hyperglycemia, dyslipidemia, proteinuria,
nephrotoxicity, delayed graft function, pneumonitis, anemia, hypertension, gonadal dysfunction, and ovarian
toxicity. Strategies for selecting appropriate patients for mTOR inhibitor therapy and minimizing the risks of
AEs are discussed, along with best practices for identifying and managing side effects. mTOR inhibitors are
promising therapeutic options in immunosuppression and oncology; most AEs can be effectively detected and
managed or reversed with careful monitoring and appropriate interventions.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The mammalian target of rapamycin (mTOR) inhibitors sirolimus
and everolimus are potent immunosuppressors used to prevent acute
rejection following solid-organ transplantation [1]. These drugs target
signal transduction pathways involved in cell-cycle progression,
thereby inhibiting interleukin-2–induced T-cell proliferation. mTOR
inhibitors also block enzymes in cell-cycle signal transduction pathways
that play a role in the development and progression of certain cancers.
The mTOR inhibitors everolimus, temsirolimus, and ridaforolimus have
demonstrated antitumor activity in various cancers, most notably
advanced renal cell carcinoma [2–4]. However, some mechanisms
associated with the immunosuppressive and anticancer properties of
mTOR inhibitors are also linked to the progression of many disorders,
including metabolic (eg, diabetes, hyperlipidemia) [5], renal (eg,
proteinuria, delayed graft function [DGF]) [6–8], dermatologic/mucosal
(eg, stomatitis, rash) [9], hematologic (eg, anemia, microcytosis) [10],
hemodynamic (eg, hypertension) [11], and hormonal conditions (eg,
impaired gonadal function, ovarian toxicity) [12,13], aswell as impaired
wound healing (eg, lymphocele, hernia) [14]. This review explores the⁎ Corresponding author at: Center for Transplantation, University of Kansas Medical
Center, Kansas City, KS 66160, USA. Tel.: +1 913 588 2516.
E-mail address: bkaplan@kumc.edu (B. Kaplan).
http://dx.doi.org/10.1016/j.trre.2014.03.002
0955-470X/© 2014 The Authors. Published by Elsevier Inc. This is an open access article umechanistic causes of adverse events (AEs) associated with mTOR
inhibitors and presents strategies for managing these events.
2. Literature search methods and results
An initial PubMed searchwas conducted to evaluate the overall scope
of AEs associated with mTOR inhibitors using the following search
criteria: {(everolimusOR sirolimusORmTOR[Title])ANDadverse events
[Title/Abstract]} AND English[Language]. Based on the initial literature
review, additional PubMed searches were performed of the most
common AEs and those of clinical interest using the following search
terms: {(everolimus OR sirolimus) AND “AE name”[Title/Abstract]},
where “AE name” = proteinuria (196 articles), hypertension (183
articles), hyperlipidemia (132 articles), pneumonitis (128 articles),
anemia (122 articles), wound healing (82 articles), stomatitis (82
articles), delayed graft function (74 articles), rash (72 articles),
hyperglycemia (68 articles), new-onset diabetes (42 articles), lympho-
cele (32 articles), and follicle-stimulating hormone (FSH) OR luteinizing
hormone (LH) (6 articles). Two recently published and relevant articles
not identiﬁed in the PubMed searches also were included in this review.
Articles were limited to those in the English language.
After removing duplicates, the identiﬁed abstracts were reviewed
for potential relevance. Full-text articles were obtained for 104
references with details on the incidence of, mechanistic features of,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
127B. Kaplan et al. / Transplantation Reviews 28 (2014) 126–133and/or strategies for managing speciﬁc AEs. The following sections
summarize the literature ﬁndings and present strategies to prevent
and manage these AEs, based on the authors' clinical experience.3. Dermatologic and mucosal adverse events
3.1. Stomatitis
Oral ulcerations are a commondose-limiting toxicity associatedwith
mTOR inhibitors [9]. It is thought that these ulcers result from direct
toxic effects of mTOR inhibitors on oral and nasal mucous membranes
[15]. These AEs are distinct from the conventional mucositis seen with
chemotherapy, with clinical ﬁndings resembling aphthous stomatitis
[16]. mTOR inhibitor-associated stomatitis (mIAS) typically presents as
distinct, painful, ovoid, superﬁcial ulcers surrounded by a characteristic
erythematous margin [16]. The ulcers are generally grayish-white
lesions of b1 cm in diameter that form on the inner lip, ventral and
lateral surfaces of the tongue, and the soft palate [16]. Unlike viral ulcers,
mIAS lesions do not form on more keratinized mucosa, such as the
gingiva and dorsal surface of the tongue [16]. mIAS ulcers usually form
soon after initiation of mTOR inhibitor therapy (median time to onset
with sirolimus is reportedly 1 week) [15].
In transplant recipients and cancerpatients, the incidenceofmIAS can
be up to 60%, but most AEs are not severe (≤5% are Grade 3 or 4) and
typically do not require discontinuation of therapy [15,17,18]. According
to the prescribing information and safety results from pivotal Phase 3
transplantation studies, the incidence of stomatitis/mouth ulceration is
between 3% and 8% with everolimus (Table 1) [18–30]. The incidence of
oral ulceration in pivotal studies of sirolimus reportedly ranges from 10%
to 19% (Table 1) [31]; however, the mucosal lesions were attributed toTable 1
Incidence of adverse events of interest in pivotal transplantation studies of everolimus
or sirolimus [18–30].
Adverse event Everolimus (0.75 or 1.0 mg
BID with reduced- or
standard-dose TAC or CsA)a
Sirolimus (2 or 5 mg with
CsA ± corticosteroids)
Dermatologic disorders
Acne 5%–14% 10%–25%
Stomatitis/oral ulcers 3%–8% 10%–19%b
Rash NR 5%–10%
Wound-healing disorders
Any wound-healing event 11%–35% 3%–36%
Lymphocele 7%–16%c 5%–20%
Wound dehiscence 1.5% NR
Incisional hernia 3% 18%
Metabolic disorders
Hyperglycemia 12%–14% NR
New-onset diabetes
mellitus
5%–32% 20%–27%
Hyperlipidemia 21%–24% 30%–64%
Hypertriglyceridemia 4% 21%–57%
Hypercholesterolemia 16%–17% 20%–46%
Dyslipidemia 15% NR
Renal disorders
Proteinuria 3%–36%c 9%–10%
Nephrotic syndrome NR 2%
Pulmonary disorders
Pneumonitis 0%–7% 0%–5%
Blood and lymphatic disorders
Anemia 8%–26% 11%–27%
Leucopenia 3%–12% 5%–12%
Thrombocytopenia 5% 6%–23%
Hemodynamic disorders
Hypertension 17%–30% 21%–38%
Abbreviations: BID, twice daily; CsA, cyclosporine; NR, not reported; TAC, tacrolimus.
a Where possible, data are reported for approved doses: 0.75 mg BID for kidney
transplantation and 1.0 mg BID for liver transplantation.
b Reported as unconﬁrmed herpes simplex virus.
c Range included everolimus up to 3.0 mg/d.unconﬁrmedherpes simplex viral infection [19,20]. Further, there iswide
variability across the literature in the incidence of AEs involving mucous
membranes (ranging from 10% to 100% with sirolimus), possibly due to
underreporting of mild AEs and/or to differences in underlying
conditions (eg, psoriasis, diabetesmellitus), AEclassiﬁcations (eg, herpes,
aphthous ulceration, oral erosions, ulcerations), and treatment protocols
[15,31]. Several studies showed no clear differences in the incidence or
severity of mucositis AEs between everolimus, sirolimus, temsirolimus,
or ridaforolimus [18,32].
Aphthous ulceration is especially common in transplant recipients
who are switched from a calcineurin inhibitor (CNI) to sirolimus and in
patients on combination therapy with sirolimus and mycophenolate
mofetil (MMF) [15,31]. The incidence of stomatitis in these patients is
reportedly as high as 60% [31,33]. There are 2 possible explanations for
the high incidence of stomatitis in such cases: (1) antiviral prophylaxis
and high-dose steroid therapy given immediately after transplantation
may reduce viral or inﬂammatory cofactors, thereby reducing the
incidence of mIAS, and (2) long-standing CNI immunosuppressive
therapy may result in mucous membrane fragility that is enhanced by
introducing an mTOR inhibitor [15,33].
Strategies to prevent oral mIAS include maintaining good oral
hygiene with gentle brushing, mild toothpaste (without sodium lauryl
sulfate or strong ﬂavors), and salt and baking soda rinses; avoiding
spicy, acidic, hot, or hard foods; reducing stress; and avoiding harsh
agents (eg, peroxide, antifungals, alcohol, iodine, thyme) [9,31,34–36]. If
identiﬁed early, mIAS generally responds well to treatment [9,31,37].
Topical high-potency corticosteroids (eg, clobetasol, dexamethasone),
nonsteroidal anti-inﬂammatory drugs (NSAIDs; eg, amlexanox paste),
and anesthetics (eg, Miracle mouthwash, viscous lidocaine) can be
used to promote healing and reduce pain [9]. Persistent or recurrent
mIAS can be managed with intensive topical, intralesional, or systemic
corticosteroids; or systemic colchicine, pentoxifylline, or azathioprine
[9]. Grade 2 or higher mIAS is generally painful and may restrict oral
intake of nutrients; in such cases, mTOR inhibitor dose reduction or
cessation may be required [9]. If lesions persist after aggressive
treatment and withdrawal of mTOR inhibitor therapy, patients should
be referred to an oral surgeon to exclude cancer [31].
3.2. Other cutaneous adverse events
Other common dermatologic effects of mTOR inhibitors include
acne-like dermatitis, pruritus, rash, and nail changes (Table 1) [31,38].
These AEs may result from mTOR inhibitor blockade of the epidermal
growth factor pathway and may resolve spontaneously [39]. More
persistent AEs typically can be managed with standard topical or
systemic therapies and rarely lead to discontinuation ofmTOR inhibitor
therapy [31,39]. Physicians should actively monitor patients for
dermatologic side effects because early intervention can minimize
bothersome symptoms and cosmetic problems, and prevent more
severe cutaneous AEs [31].
4. Wound-healing adverse events
Surgical complications, including wound dehiscence, incisional
hernia, lymphocele, and infection, that can impair wound healing
have been reported in 15% to 32% of kidney transplant and 8% to 40% of
heart transplant recipients [14,40]. Higher rates of incisional hernia and
lymphocele have occurred with mTOR inhibitors relative to other
immunosuppressants when patients received a high loading dose of
mTOR inhibitor [14,41,42]. However, more recent studies using lower
doses of mTOR inhibitors without a loading dose have shown that rates
of wound-healing complications do not differ signiﬁcantly between
mTOR inhibitors and other immunosuppressive therapies [14]. For
example, in the H2304 study inwhich everolimuswas initiated 30 days
after liver transplantation, the rate of wound complication was 11.0%
(27/245) for everolimus plus low-dose tacrolimus, compared with 7.9%
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everolimus 1.5 mg or 3.0 mg versusmycophenolic acid (MPA) initiated
within 48 hours of kidney transplantation, the rate of wound
complications was signiﬁcantly greater for the higher everolimus dose
compared toMPA (21.8% vs 14.3%; p b 0.001) but not for the lower dose
(16.6% vs 14.3%; p = 0.255) [29]. Incidences of wound-healing
complications in pivotal studies of solid-organ transplantation are listed
in Table 1.
mTOR inhibitors block growth signals required for proliferation of
endothelial cells and ﬁbroblasts, thereby restricting ﬁbrosis, which is a
key factor in successful wound healing [14,43]. mTOR inhibitors also
inhibit vascular endothelial growth factor (VEGF) andnitric oxide,which
are mediators of angiogenesis, inﬂammation, and immune function in
skin wounds [43,44]. Sirolimus has also been shown to disrupt skin T-
cell proliferation, migration, and production of growth factors [45,46].
Factors that increase the risk of mTOR inhibitor-associatedwound-
healing AEs are advanced age, diabetes, malnourishment, corticoste-
roid or anticoagulant use, high bodymass index (BMI), thymoglobulin
induction, and long surgery duration [41,47]. Risk factors for incisional
hernia in liver transplant patients receiving mTOR inhibitor therapy
include male gender, BMI ≥ 29 kg/m2, Model for End-Stage Liver
Disease (MELD) score ≥ 22, hepatitis B virus positivity, and receipt of
a deceased donor graft [44].
Delaying mTOR inhibitor therapy until 3 to 7 days posttransplanta-
tion and avoiding high loading doses (which is consistent with
everolimus usage and administration guidelines) [27] have signiﬁcantly
reduced the risk of impaired wound healing, particularly for obese or
diabetic patients [40,43,48]. Everolimus is not indicated for administra-
tion until at least 30 days after liver transplantation [27] becausemTOR
inhibitors dose-dependently impair vascularization [44]. Furthermore,
most complications develop during the ﬁrst few postoperative months.
At ≥ 30 days posttransplantation, wounds should be somewhat healed
and wound strength should be developing; the risks of wound
complications associated with newly initiated mTOR inhibitor therapy
at this stage should be minimal [42,44].
Reducing obesity before transplantation (if possible) may reduce
the risk of wound complications [48]. For kidney transplant recipients,
performing surgery prior to initiating dialysis is recommended [47].
Minimizing the use of corticosteroids is recommended to reduce the
risk of wound-healing delays [47,48]. If patients require subsequent
surgeries and mTOR inhibitor therapy can be safely interrupted, the
risk of wound-related AEs may be reduced by stopping mTOR
inhibitor therapy at least 1 week before surgery and resuming it 10
to 15 days afterward [49].
Surgical techniques reported to improvewound-healing outcomes in
transplant recipients include placing closed-suction drains, using
subcutaneous sutures, sealing or ligating lymphatic ducts, performing
prophylactic peritoneal fenestration, and avoiding extensive dissection;
careful attention to surgical technique also is important [41,43,47,49–51].
If used, staples can remain in place for 3 to 4 weeks to prevent skin
dehiscence [41]. If a symptomatic lymphocele develops, ultrasonography
should be performed to determine if intervention is required. Interven-
tion is needed if ﬂow to the kidney is impacted, hydronephrosis is found,
there is radiologic or clinical evidence of an infected ﬂuid collection, or
the recipient develops unilateral swelling of the ipsilateral leg. Treatment
options for symptomatic lymphoceles include percutaneous aspiration
(with or without sclerotherapy) and surgical marsupialization of the
lymphocele into the peritoneal cavity [50], which can be performed
open or laparoscopically. If lymphoceles are associated with deep vein
thrombosis, anticoagulation therapy or a vena caval ﬁlter may be
required [50].
Incisional hernias can be repaired using laparoscopic or open
techniques [52], with biologic or synthetic mesh closures [53]. Because
the risk of infection is higher in immunosuppressed transplant
recipients, biologic mesh is a viable option for them. If a mesh-related
infection develops after hernia repair, having used biologicmesh allowsfor treating the infection with antibiotics as opposed to removing a
synthetic mesh via another complex operation [54].
5. Lymphedema
mTOR inhibitors can impair lymphoangiogenesis, such that lymph
ﬂuid is not contained in the lymph system. This can lead to
lymphocele development, as described above, and to the rare but
serious AEs of lymphedema and capillary leakage [41,55]. Patients
taking mTOR inhibitors should be monitored for lymphedema;
treatment should be withdrawn promptly at the ﬁrst sign of ﬂuid
accumulation because severe lymphedema is not always reversible
and can be fatal [55]. Evidence suggests that patients with preexisting
lymphatic deﬁciencies should not use mTOR inhibitors [55].
6. Metabolic adverse events
6.1. Hyperglycemia
Hyperglycemia and new-onset diabetes mellitus (NODM) are well-
recognized posttransplant complications that increase cardiovascular
events, all-cause mortality, and cardiovascular mortality [56]. There is a
strong association between immunosuppression andNODM, particularly
when immunosuppressive regimens include the CNI tacrolimus [57,58].
The associationbetweenmTOR inhibitors andNODMis less clear, and the
risk of developing NODM may differ depending on whether a CNI is
combined with an mTOR inhibitor. In a retrospective analysis of data
from the US Renal Data System (N = 20,124 renal transplant patients),
sirolimus was independently associated with an increased risk of
NODM [59]. However, in randomized controlled trials of everolimus
with low-dose cyclosporine (with or without basiliximab) in renal
transplant recipients, the incidence of NODM was low (≤5%) [60,61].
The pathophysiology of mTOR inhibitor-induced NODM is com-
plex. mTOR and its downstream target S6 kinase 1 (S6K1) interact
with various growth factors, hormones, and nutrients to regulate
protein translation and cell growth, proliferation, and survival [5,62].
In animal models, sirolimus induces NODM by increasing insulin
resistance, glucose intolerance, and gluconeogenesis, and reducing
β-cell function [5,62].
Recent data suggest that patients with risk factors for diabetes (eg,
advanced age, Black race, Hispanic ethnicity, obesity, family history of
diabetes, hepatitis C positivity, transplantation from deceased donor)
[59] be monitored closely for NODM throughout mTOR inhibitor
therapy. Glucosemonitoring (preferably fasting) should be performed
regularly to identify new or worsening hyperglycemia [63]. Other
symptoms that indicate hyperglycemia include increased thirst and
urination [63–65]. Education strategies should be implemented so
that patients learn to recognize these symptoms [65]. If possible,
efforts should be made to establish normoglycemia before starting
mTOR inhibitors [36,65].
The2012position statement from theAmericanDiabetes Association
and the European Association for the Study of Diabetes [66] provides
practical guidelines for managing type 2 diabetes. Although these
guidelines do not speciﬁcally address NODM associated with mTOR
inhibitors in cancer or transplant patients, management strategies are
similar for all causes of diabetes [66]. A patient-centered approach is
emphasized,with individualized treatmentgoals basedoneachpatient's
overall health, medication tolerance, and preferences [66]. Treatment
algorithms include diet and exercise modiﬁcations, followed by use of
oral antihyperglycemic agents and insulin [36,51,65,66]. If sustained
hyperglycemia develops despite diet and exercise modiﬁcations,
metformin is usually recommended as ﬁrst-line treatment; however,
metformin is contraindicated in patients with renal impairment
(estimated glomerular ﬁltration rate [eGFR] b 60 mL/min), signiﬁcantly
impaired liver function, and states of decreased tissue perfusion
(eg, myocardial infarction, sepsis) [63].
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transplant recipients and patients with advanced cancer. Patients
treated with sulfonylureas or insulin should be monitored closely for
hypoglycemia, and less aggressive glycemic goals (hemoglobinA1c level
[HbA1c ≤ 8%]) may be appropriate for critically ill patients compared
with the general diabetes population (HbA1c ≤ 7%) [63]. If patients
discontinue mTOR inhibitor therapy for any reason, careful adjustment
of antihyperglycemic treatments is needed to avoid hypoglycemia [63].
6.2. Hyperlipidemia
Hyperlipidemia is very common with mTOR inhibitors, with
estimated prevalence of up to 75% [51,63]. Most lipid-related AEs are
mild; patients rarely experience moderate or severe increases in
cholesterol or triglycerides [36,51]. However, for patients with
established hyperlipidemia, the risk/beneﬁt ratio should be carefully
considered before starting an mTOR inhibitor [26,27]. In clinical trials
of sirolimus plus cyclosporine and sirolimus after cyclosporine
withdrawal, up to90%of patients required treatment for hyperlipidemia
and hypercholesterolemia. Despite receiving lipid-lowering therapy, up
to 50% of patients had fasting serum cholesterol levels N 240 mg/dL and
triglycerides above the recommended target levels [26]. However, a
retrospective analysis comparing the effects of everolimus versus
sirolimus on blood lipid proﬁles and hematologic events in heart
transplant patients with renal insufﬁciency (N = 55) demonstrated
that everolimus 1.5 mg/day was associated with signiﬁcantly lower
levels of triglycerides (p b 0.042) and low-density lipoprotein (p =
0.005) at 6 months compared with sirolimus 3.0 mg/day [67]. Table 1
shows the incidence of lipid-related AEs in pivotal transplantation
studies of these agents.
mTOR inhibition reduces the catabolism of circulating lipoproteins
by inhibiting the activity of lipases, resulting in dyslipidemia [51]. In
animal studies, sirolimus altered the expression of enzymes required
for fatty acid uptake and storage and triglyceride synthesis [5]. By
reducing lipid uptake and fat cell numbers, mTOR inhibition limits the
capacity of adipose tissue for plasma lipid clearance, which likely
contributes to hyperlipidemia [5].
Before initiating mTOR inhibitor therapy, lipidemic control should
be optimized and patients should be evaluated for other potential
causes of hyperlipidemia, such as hypothyroidism, nephrotic syn-
drome, and concomitant thiazide medication [36]. Patients should be
advised to limit dietary intake of saturated fat, cholesterol, simple
sugars, and alcohol, and to increase intake of soluble ﬁber and plant
sterols [63]. Strategies to reduce weight and increase physical activity
should be implemented, where possible, for overweight or obese
patients [63]. Baseline lipid proﬁles should be determined for all
patients [36,63].
Any patient taking an mTOR inhibitor should be monitored for
hyperlipidemia [26,27]. If detected, interventions such as diet,
exercise, and lipid-lowering agents should be initiated according to
the National Cholesterol Education Program guidelines [26,27,68].
These guidelines take into account various risk factors and estimate
the probability of a cardiovascular event over a period of years and
provide recommendations accordingly [68]. Detailed clinical practice
guidelines for managing dyslipidemias speciﬁcally in kidney trans-
plant recipients have been issued by the National Kidney Foundation
Kidney Disease Quality Outcomes Initiative [69].
Dyslipidemia can generally bemanagedwith combinations of lifestyle
changes, ﬁbrates, extended-release niacin, statins, omega-3-acid ethyl
esters (ﬁsh oil), and/or bile sequestrants [36,63,69]. If triglyceride levels
exceed 500 mg/dL, patients should be treated with ﬁbrates immediately
to reduce the risk of pancreatitis [36].
Cyclosporine has been associated with rhabdomyolysis and other
AEs, such as creatine phosphokinase elevation and myalgia, when
combined with HMG-CoA reductase inhibitors (eg, lovastatin,
simvastatin). Therefore, it is recommended that all patients taking astatin and/or ﬁbrate with an mTOR inhibitor be monitored for similar
side effects [26,27].
7. Renal adverse events
7.1. Proteinuria
De novo or exacerbated proteinuria occurs in up to 45% of patients
following kidney transplantation and can adversely affect transplant
outcomes [70–72]; however, the incidence of severe proteinuria is
generally low [23,71]. It is hypothesized that proteinuria correlates
with chronic allograft injury and development of glomerular lesions
[73]. Although proteinuria has been observed in some studies in
which patients received de novo sirolimus therapy [74], the condition
is particularly common upon conversion from CNI to mTOR inhibitor
therapy (especially sirolimus), possibly due to a reduction in the
vasoconstrictive effects of CNIs [72,73]. The incidence of proteinuria
and associated nephrotic syndrome in clinical studies of everolimus
and sirolimus is shown in Table 1.
The exact mechanism by which mTOR inhibitors affect glomerular
permeability is not known. Many mechanisms have been proposed,
including decreased VEGF synthesis and expression, resulting in
podocyte injury and focal segmental glomerulosclerosis; dose-related
alteration of podocyte slit diaphragm-associated protein structure
and function, resulting in loss of podocyte structural integrity; and
activation of the innate immune system, resulting in an increased
number of glomerular macrophages [6,7,73,75–77]. In preclinical
studies, sirolimus (but not everolimus) enhanced the negative effects
of cyclosporine on proximal tubule metabolism [78,79].
All patients on mTOR inhibitor therapy should be monitored for
increased urinary protein excretion. Conversion from CNI to mTOR
inhibitor therapy should be performed cautiously in patients with
existing proteinuria (N800 mg/day), eGFR b 40 mL/min, or chronic
allograft injury [6,49,73]. Immunostaining can be used to detect podocyte
toxicity in the early stages of focal segmental glomerulosclerosis [73], and
measurementof anti-human leukocyteantigen (anti-HLA)antibodies can
serve as a marker for capillary damage, proteinuria, and reduced renal
function. The presence of anti-HLA antibodies is also associatedwith poor
graft survival and insufﬁcient or ineffective immunosuppression [71].
Strategies for managing mild proteinuria include lowering blood
pressure with angiotensin-converting enzyme (ACE) inhibitors or
angiotensin II receptor blockers (ARBs), dietary sodium and protein
restriction, controlling obesity and lipids (with statins), and smoking
cessation [70–73,80]. If proteinuria increases, drug withdrawal may
be necessary to reduce the risk of acute renal failure; proteinuria
is generally reversed within a few months of mTOR inhibitor
discontinuation, and the majority of patients show no long-term
residual kidney damage [72]. If massive proteinuria develops upon
conversion from CNI to mTOR inhibitor therapy, reintroduction of CNI
therapy may reverse urinary protein loss [72,73]. Plasmapheresis may
be effective for managing patients who develop focal segmental
glomerulosclerosis or membranoproliferative glomerulonephritis [71].
7.2. Hemodynamic effects
In an animal model of chronic cyclosporine toxicity produced by
1 week of salt depletion, adding sirolimus to cyclosporine immuno-
therapy was associated with worsening of renal function and structural
injury [81]. These synergistic nephrotoxic effects may be due to
sirolimus-induced hyperglycemia, which is known to accelerate renal
tubulointerstitial ﬁbrosis and tubular atrophy [81]. In addition,
cyclosporine toxicity is related to the generation of reactive oxygen
species, and when cyclosporine is coadministered with sirolimus,
inhibition of mitochondrial energy metabolism and reactive oxygen
species production are up-regulated. In contrast, everolimus antago-
nizes cyclosporine-induced mitochondrial dysfunction, which suggests
130 B. Kaplan et al. / Transplantation Reviews 28 (2014) 126–133that, unlike sirolimus, everolimus may reduce the negative effects of
cyclosporine on mitochondrial metabolism [82].
Although theeffects ofmTOR inhibition onCNI-inducedﬁbrosis have
not been veriﬁed clinically, hemodynamic effects have been observed in
clinical trials of sirolimus and everolimus with standard-dose CNI
therapy [19,20,83]. Therefore, to minimize the risk of nephrotoxicity,
reduced doses of cyclosporine are required when used in combination
with mTOR inhibitors [27], and careful monitoring of drug dosing and
plasmaconcentrations is recommended [49]. For example, in ananalysis
of the association between everolimus and cyclosporine exposure levels
and clinical events in renal transplant recipients, Shihab and colleagues
[84] observed that the risk of nephrotoxicity and other AEs (eg, wound-
healing AEs, NODM, dyslipidemia) were lowest when trough concen-
trations ranged from 3 to 8 ng/mL for everolimus and from 25 and
50 ng/mL for cyclosporine.
7.3. Delayed graft function
DGF, deﬁned as the need for dialysis during the ﬁrst week after
transplantation, is a common complication in cadaveric renal
transplantation [41,51]. Several studies have shown that sirolimus-
containing regimens prolong recovery from DGF comparedwith other
immunosuppressive protocols [8,85,86]. However, similar ﬁndings
have not been observed with everolimus; the CALLISTO study showed
that both de novo and delayed everolimus introduction strategies
were associatedwith good renal function outcomes in patients at high
risk for DGF [87].
Sirolimus is thought to prolong recovery from DGF because of its
antiproliferative effects on growing renal epithelial cells, which
inhibit regeneration of the epithelium following ischemia/reperfusion
injury [51]. Risk factors for DGF that should be considered before
using sirolimus include receipt of a kidney from a marginal donor or
immunologic mismatch, along with patient age, body weight,
ethnicity, gender, hypotension, and previous dialysis [41]. For high-
risk patients, delaying sirolimus therapy until the transplanted kidney
is functional can eliminate the risk of sirolimus-related prolongation
of DGF [88]. The duration of sirolimus-induced DGF effects is thought
to be dose-dependent, so high loading doses of sirolimus should be
avoided, and target trough concentrations of 6 to 10 ng/mL are
recommended [41].
If persistent DGF develops during sirolimus treatment, transplant
biopsies should be performed every 1 to 2 weeks to exclude the
possibility of acute rejection. Sirolimus doses should be reduced to
trough levels of 4 to 8 ng/mL or, in severe cases, a different
immunosuppressive regimen should be used. If graft function improves,
low-dose sirolimus can be restarted 5 to 10 days after kidney function is
restored [41].
8. Pulmonary adverse events
Pneumonitis, or interstitial lung disease, is another potential
complication of mTOR inhibitors. Pneumonitis appears to be more
common in oncology than in transplant settings, possibly due to
differences in dosing regimens or more frequent radiographic moni-
toring of cancer patients, leading to increased detection [80,89]. Among
patients with advanced renal cell carcinoma, pneumonitis rates of up to
14% have been reported with everolimus [89]. In solid-organ transplant
recipients, pulmonary toxicity is considered a rare but serious side effect
of sirolimus andeverolimus, describedprimarily in case reports [90–92].
Case reports of pneumonitis are much less common in transplant
patients receiving everolimus versus sirolimus, and sirolimus-related
pneumonitis reportedly resolves after conversion to everolimus [80,92].
Pneumonitis is a noninfectious, nonmalignant inﬁltration of the
lungs that presents as ground-glass opacities and focal consolidation
on x-ray [34,36]. The most common symptoms of interstitial lung
disease include dry cough and exertional dyspnea; fever, night sweats,fatigue, respiratory distress, and hemoptysis also may occur [90,91].
Arterial blood gas measurements often reveal hypoxemia, and
pulmonary function tests may show reduced capacity for diffusing
carbon monoxide [90]. Histologic changes associated with mTOR
inhibitor-related pulmonary toxicity may include organizing pneu-
monia, pulmonary alveolar proteinosis, focal ﬁbrosis, and alveolar
hemorrhage [91]. The onset of mTOR inhibitor-related pneumonitis
typically occurs within 2 to 6 months after treatment initiation [36].
The exact pathogenic mechanism of mTOR inhibitor-induced
pulmonary toxicity is not known. Possible mechanisms include direct
damage to alveolar structures, formation of immunogenic haptens,
and direct immunologic drug responses (based on observed high
levels of CD4-positive cells in bronchoalveolar lavage) [91]. Pulmo-
nary toxicity appears to be dose-related, and an observed slight male
predominance of sirolimus-related pulmonary AEs is consistent with
the drug's longer half-life in males versus females [90].
In patients with respiratory symptoms at baseline, pulmonary
function tests should be performed prior to starting mTOR inhibitor
therapy; treatment should be initiated only if lung function is normal
[36]. mTOR inhibitors should be avoided in patients with signiﬁcant
pulmonary ﬁbrosis or severe chronic obstructive pulmonary disease
[36]. If mTOR inhibitor-related pneumonitis is suspected, it is important
to rule out infection, parasites, autoimmune disorders, and other
pulmonary diseases [90,91]. mTOR inhibitor-associated pulmonary
toxicity should be a diagnosis of exclusion [90,91]. If patients present
with fever, titration of infectionbiomarkers (eg, procalcitonin)mayhelp
discriminate between infectious and noninfectious disease [36].
Grade1 (asymptomatic) interstitial lungdisease shouldbemonitored
closely with frequent (every 4–8 weeks) radiographic and pulmonary
function assessments [65]. mTOR inhibitor dose reductions, corticoste-
roids (eg, prednisone 1 mg/kg), and antibiotics may be required for
Grade 2 (symptoms not interfering with daily activities, and oxygen
support not required) or Grade 3 (symptoms interfere with daily
activities and/or oxygen support required) toxicities [34,65,90]. Clinical
improvement is often rapid after mTOR inhibitor discontinuation;
complete radiographic resolution of pneumonitis is frequently observed
within 2 to 4 months [91,92].
If pneumocystis pneumonia is suspected in patients with mTOR
inhibitor-associated pneumonitis, treatment with pentamidine
should be avoided because interactions with sirolimus reportedly
cause drug-induced phospholipidosis and rapid clinical deterioration.
Instead, treatment with trimethoprim/sulfamethoxazole or clinda-
mycin/primaquine is recommended [93].
9. Hematologic adverse events
9.1. Anemia
Posttransplant anemia occurs in 12% to 76% of renal transplant
recipients [94]. ImmunosuppressionwithmTOR inhibitors can promote
anemia and delay improvement in hemoglobin levels after surgery [94].
Anemia associated with mTOR inhibitors is characterized by micro-
cytosis (ie, marked decline in mean corpuscular volume of red blood
cells [RBCs]) and low serum iron levels [10,95,96]. It is generally mild,
dose-dependent, and reversible upon discontinuation of treatment [10].
Anemia generally presents early in the course ofmTOR inhibitor therapy
(within a month of initiation) and is sustained throughout treatment
[10]. Other risk factors for anemia include advanced age, low iron status,
malignancies, inﬂammation, renal dysfunction, viral infections, and
combined use of mTOR inhibitors and MMF (MMF is associated with
signiﬁcantly higher rates of anemia vs other immunosuppressants)
[94,96–98].
It is hypothesized that mTOR inhibitor-related anemia results from
disruptions in iron homeostasis and gastrointestinal iron absorption,
as well as effects on erythroid progenitor cell differentiation and
erythropoietin receptor-mediated proliferation of erythroid precursors
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precursors and reduced globin synthesis [94].
Anemia screening every 1 to 3 months is recommended for patients
taking mTOR inhibitors. If anemia is detected, its cause should be
determined. Stools shouldbe tested for the presence of occult blood, and
screenings should be conducted to detect possible malignancies. RBC
indices, reticulocyte count, and levels of vitamin B12 and folate should be
measured [94]. Patients should also be evaluated for hemolytic–uremic
syndrome, a rare complication of cyclosporine treatment [94]. If there is
no evidence of infection, inﬂammation, malignancy, or nutritional
defects,mTOR inhibitor-related anemia shouldbe considered, especially
if microcytosis is present.
If iron deﬁciency is present (eg, serum ferritin b 100 ng/mL
and transferrin saturation b 20% or reticulocyte hemoglobin con-
tent b 29 pg/cell), oral supplementation should be considered
(≥200 mg/day of elemental iron), with careful monitoring to avoid
iron overload [94,98]. If oral supplementation is not effective,
intravenous iron should be considered [94]. Erythropoiesis-stimulating
agents may also be effective for managing mTOR inhibitor-associated
anemia [98]. If iron supplementation and/or erythropoiesis-stimulating
agents are not sufﬁcient to manage anemia, mTOR inhibitor therapy
should be reduced or discontinued [94].
9.2. Thrombocytopenia and leucopenia
Thrombocytopenia and leucopenia/neutropenia have been reported
with mTOR inhibitor therapy, especially when combined with myco-
phenolate therapy [99]. These AEs frequently occur simultaneously and
usually resolve spontaneously [100]. Complete blood counts should be
obtained regularly to monitor for these AEs. Management of thrombo-
cytopenia involves minimizing procedures that increase bleeding risk
and avoiding aspirin, ibuprofen, and NSAIDs [35]. To prevent infections,
patients with neutropenia should be counseled to wash their hands
frequently and avoid exposure to germs. Grade 3 or higher neutropenia
or thrombocytopenia may require temporary interruption of mTOR
inhibitor therapy [35,49].
10. Hypertension
Posttransplant hypertension is associated with immunosuppressive
therapy and declining renal function, alongwith a range of other factors,
such as renal artery stenosis, antibody-mediated rejection, chronic
allograft injury, and proteinuria [11,101]. Donor age and graft quality, as
well as recipient age, gender, diabetes, BMI, pretransplant hypertension,
and primary kidney disease, are factors that can inﬂuence the risk of
hypertension [101]. CNIs are known to promote hypertension because
they increase oxidative stress and sympathetic activation, which may
cause afferent arteriolar vasoconstriction [101]. Nephrotoxicity and
chronic allograft injury associated with CNI therapy may also increase
the risk of hypertension [101]. It has been postulated that CNI
minimization with mTOR inhibition may reduce the incidence of
hypertension comparedwith standard-doseCNI, butdata are conﬂicting,
and randomized controlled trials are needed to conﬁrm this [101].
Hypertension is a common side effect of mTOR inhibitors (Table 1), but
pivotal clinical trials showed nomeaningful increase in the incidence of
hypertension versus comparator agents [21,22,25].
Optimalmanagement of hypertension after transplantation includes
manipulating immunotherapy (when possible) to reduce exposure to
cyclosporine, often with conversion to sirolimus or everolimus [11].
However, even with an optimized immunosuppressive regimen that
minimizes drug-related hypertension,most patients still require at least
one antihypertensivemedication to control blood pressure. Vasodilatory
calcium-channel blockers (eg, nifedipine) are often considered ﬁrst-line
agents for posttransplant hypertension because positive interactions
with immunosuppressants may reduce the requirement for CNIs or
mTOR inhibitors and reduce nephrotoxicity. Beta-blockers are alsorecommended, particularly for patients with congestive heart failure
or history of myocardial infarction. Although ARBs and ACE inhibitors
may also be effective, and can reduce the incidence of proteinuria, they
should be used cautiously because they can exacerbate reductions
in GFR, hyperkalemia, and anemia [11]. In addition, increased rates of
angioedema were noted when ACE inhibitors were combined with
mTOR inhibitors [102].
11. Reproductive endocrine adverse effects
11.1. Effects in Men
Sirolimus and everolimus have been shown to delay the improve-
mentof gonadal functionafter transplant surgery, resulting in decreased
fertility, sexual hormone dysfunction, decreased ejaculate volume, and
low sperm count or azoospermia [103,104]. Testosterone deﬁciency is
also associated with increased levels of FSH and LH [13,105]. The
incidence of gonadal AEs is not known with certainty; these AEs were
not reported in pivotal controlled trials. Sirolimus prescribing informa-
tion lists reversible azoospermia as a possible AE [26], and decreased
serum testosterone and increased FSH have occurred with everolimus,
with 5% of patients reporting erectile dysfunction compared with 2% of
controls [27].
The underlying mechanism of adverse gonadal effects is thought to
relate to mTOR inhibitor suppression of p70 S6 kinase, which regulates
germ-cell proliferation, meiosis, and apoptosis [13]. In animal models,
sirolimus reduced testicular weight, altered the morphology of
seminiferous tubules, and decreased spermatogenesis and testosterone
levels. These effects were dose-related and worsened over time, but
were reversed within 8 weeks of cessation of sirolimus [103].
Data on the clinical implications of reduced fertility and erectile
function inmen treatedwithmTOR inhibitors are limited. No published
guidelines were identiﬁed for the management of gonadal AEs.
Discontinuation of mTOR inhibitor therapy is suggested to reverse
these effects; limited evidence suggests that replacing mTOR inhibitors
with tacrolimus may normalize hormone levels. Glucocorticoids may
worsen the gonadal effects of mTOR inhibitors because they are known
to decrease testosterone synthesis [105].
11.2. Effects in women
Menstrual-cycle disturbances, including amenorrhea and menor-
rhagia, have occurred in women treated with sirolimus [12,26], and
ovarian cysts have been reported with sirolimus and everolimus
[26,27]. High rates of ovarian cysts (52%) and oligoamenorrhea (57%)
have been noted for patients receiving low doses of sirolimus (mean
doses: 1.2–1.5 mg/day) [12]. However, such AEs were not assessed in
pivotal clinical trials of mTOR inhibitors [12].
In animal models, sirolimus ampliﬁed signaling in ovarian follicles
through the phosphatidylinositol-3 kinase pathway [12]. However,
serum FSH and LH levels were similar for sirolimus recipients and
controls [12].
Treatment guidelines for the management of female endocrine AEs
are limited, but evidence suggests that these effects generally resolve
afterwithdrawal ofmTOR inhibitor therapy (eg, cyst sizewas reduced in
80% of patients) [106]. Observed ovarian cysts are generally benign, but
may require surgery and may recur [106,107]. The risks of ovarian
toxicity should be discussed with mTOR inhibitor candidates, and
patients shouldbemonitored for thedevelopmentof theseAEs [12,106].
12. Conclusions
Although challenges are associated with managing the AEs caused
by mTOR inhibitors, these immunosuppressants signiﬁcantly reduce
the risk of nephrotoxicity and malignancy in solid-organ transplant
recipients relative to CNIs. mTOR inhibitors have become the standard
132 B. Kaplan et al. / Transplantation Reviews 28 (2014) 126–133of care for patient with advanced renal cell carcinoma, with good
tolerability compared with other chemotherapeutic agents.
This article summarized the current understanding of the
mechanisms associated with mTOR inhibitor-related AEs, and
described strategies to effectively manage many common AEs. As
with all immunosuppressive and antineoplastic therapies, careful
proactive monitoring is required to reduce the risk of serious or
irreversible AEs. However, most AEs associated with mTOR inhibitors
are moderate or mild and dose-related, and many are reversible upon
cessation of treatment. Patients should be well educated on the
potential side effects of mTOR inhibitors, and the decision for their use
should be based on individual patient characteristics and risk factors.
Acknowledgments
Technical assistance with editing, ﬁgure preparation, and styling of
the manuscript for submission was provided by Oxford PharmaGenesis
Inc. and was funded by Novartis Pharmaceuticals Corporation. The
authorswere fully responsible for all content and editorial decisions and
received no ﬁnancial support or other form of compensation related to
the development of this manuscript. The opinions expressed in the
manuscript are those of the authors, and Novartis Pharmaceuticals had
no inﬂuence on the contents.
Conﬂicts of interest: B. Kaplan has received a grant from Novartis.
Y. Qazi has served as a speaker for Novartis. J.R. Wellen has served as a
speaker for Novartis.
References
[1] Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or
leaving the ﬁeld? J Nephrol 2010;23:133–42.
[2] Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic
renal cell carcinoma: ﬁnal results and analysis of prognostic factors. Cancer
2010;116:4256–65.
[3] Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for
advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.
[4] Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm
Des 2012;18:2766–77.
[5] Houde VP, Brûlé S, FestucciaWT, et al. Chronic rapamycin treatment causes glucose
intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and
impairing lipid deposition in adipose tissue. Diabetes 2010;59:1338–48.
[6] Schönenberger E, Ehrich JH, Haller H, Schiffer M. The podocyte as a direct target
of immunosuppressive agents. Nephrol Dial Transplant 2011;26:18–24.
[7] Cinà DP, Onay T, Paltoo A, et al. Inhibition of MTOR disrupts autophagic ﬂux in
podocytes. J Am Soc Nephrol 2012;23:412–20.
[8] Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays
the recovery from delayed graft function but does not affect 1-year graft
function. J Am Soc Nephrol 2004;15:228–33.
[9] Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister N. Managing stomatitis in
patients treated with Mammalian target of rapamycin inhibitors. Clin J Oncol
Nurs 2011;15:E83–9.
[10] Sofroniadou S, Kassimatis T, Goldsmith D. Anaemia, microcytosis and sirolimus—is
iron the missing link? Nephrol Dial Transplant 2010;25:1667–75.
[11] Mangray M, Vella JP. Hypertension after kidney transplant. Am J Kidney Dis
2011;57:331–41.
[12] Braun M, Young J, Reiner CS, et al. Low-dose oral sirolimus and the risk of
menstrual-cycle disturbances and ovarian cysts: analysis of the randomized
controlled SUISSE ADPKD trial. PLoS One 2012;7:e45868.
[13] Kaczmarek I, Groetzner J, Adamidis I, et al. Sirolimus impairs gonadal function in
heart transplant recipients. Am J Transplant 2004;4:1084–8.
[14] Nashan B, Citterio F. Wound healing complications and the use of mammalian
target of rapamycin inhibitors in kidney transplantation: a critical review of the
literature. Transplantation 2012;94:547–61.
[15] Mahé E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant
recipients receiving sirolimus-based therapy. Transplantation 2005;79:476–82.
[16] Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization
of oral lesions associated with inhibitors of mammalian target of rapamycin in
cancer patients. Cancer 2010;116:210–5.
[17] van den Eertwegh AJ, Karakiewicz P, Bavbek S, et al. Safety of everolimus by
treatment duration in patients with advanced renal cell cancer in an expanded
access program. Urology 2013;81:143–9.
[18] Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N,
Arias M. Comparative analysis of adverse events requiring suspension of mTOR
inhibitors: everolimus versus sirolimus. Transplant Proc 2010;42:3050–2.
[19] Kahan BD. Efﬁcacy of sirolimus compared with azathioprine for reduction of
acute renal allograft rejection: a randomised multicentre study. The Rapamune
US Study Group. Lancet 2000;356:194–202.[20] MacDonald AS, The RAPAMUNE Global Study Group. A worldwide, phase III,
randomized, controlled, safety and efﬁcacy study of a sirolimus/cyclosporine
regimen for prevention of acute rejection in recipients of primary mismatched
renal allografts. Transplantation 2001;71:271–80.
[21] De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus
improves renal function in de novo liver transplant recipients: a randomized
controlled trial. Am J Transplant 2012;12:3008–20.
[22] Langer RM, Hené R, Vitko S, et al. Everolimus plus early tacrolimus minimization:
a phase III, randomized, open-label, multicentre trial in renal transplantation.
Transpl Int 2012;25:592–602.
[23] Tedesco Silva Jr H, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure
CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant
recipients. Am J Transplant 2010;10:1401–13.
[24] Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH. Decreased acute rejection and
improved renal allograft survival using sirolimus and low-dose calcineurin
inhibitors without induction therapy. Int J Artif Organs 2009;32:371–80.
[25] Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin
inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal
transplantation. Transplantation 2004;77:1228–35.
[26] Rapamune (sirolimus) oral solution and tablets [prescribing information].
Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2011.
[27] Zortress (everolimus) tablets for oral use [prescribing information]. East
Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
[28] Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in
sirolimus-treated renal transplant recipients. Clin Transplant 2007;21:460–5.
[29] Cooper M, Wiseman AC, Zibari G, et al. Wound events in kidney transplant
patients receiving de novo everolimus: a pooled analysis of three randomized
controlled trials. Clin Transplant 2013;27:E625–35.
[30] Wiseman AC, McCague K, Kim Y, Geissler F, Cooper M. The effect of everolimus
versus mycophenolate upon proteinuria following kidney transplant and
relationship to graft outcomes. Am J Transplant 2013;13:442–9.
[31] Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockﬂeth E.
mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant
2010;24:149–56.
[32] Martins F, de Oliveira MA, Wang Q, et al. A review of oral toxicity associated with
mTOR inhibitor therapy in cancer patients. Oral Oncol 2013;49:293–8.
[33] van Gelder T, ter Meulen CG, Hené R,WeimarW, Hoitsma A. Oral ulcers in kidney
transplant recipients treated with sirolimus and mycophenolate mofetil.
Transplantation 2003;75:788–91.
[34] Creel PA. Management of mTOR inhibitor side effects. Clin J Oncol Nurs
2009:19–23.
[35] Alasker A, Meskawi M, Sun M, et al. A contemporary update on rates and
management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Cancer Treat Rev 2013;39:388–401.
[36] Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with
the use of everolimus in patients with advanced renal cell carcinoma. Eur J
Cancer 2011;47:1287–98.
[37] de Oliveira MA, Martins e Martins F, Wang Q, et al. Clinical presentation and
management ofmTOR inhibitor-associated stomatitis. Oral Oncol 2011;47:998–1003.
[38] Ramirez-Fort MK, Case EC, Rosen AC, Cerci FB, Wu S, Lacouture ME. Rash to the
mTOR inhibitor everolimus: systematic review and meta-analysis. Am J Clin
Oncol 2012 [Epub ahead of print].
[39] Mahé E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation
treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and
pathogenic aspects. J Am Acad Dermatol 2006;55:139–42.
[40] Zuckermann A, Barten MJ. Surgical wound complications after heart transplan-
tation. Transpl Int 2011;24:627–36.
[41] Campistol JM, Cockwell P, Diekmann F, et al. Practical recommendations for the
early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int
2009;22:681–7.
[42] Pengel LH, Liu LQ, Morris PJ. Do wound complications or lymphoceles occur more
often in solid organ transplant recipients on mTOR inhibitors? A systematic
review of randomized controlled trials. Transpl Int 2011;24:1216–30.
[43] Tiong HY, Flechner SM, Zhou L, et al. A systematic approach tominimizing wound
problems for de novo sirolimus-treated kidney transplant recipients. Transplan-
tation 2009;87:296–302.
[44] Montalti R, Mimmo A, Rompianesi G, et al. Early use of mammalian target of
rapamycin inhibitors is an independent risk factor for incisional hernia
development after liver transplantation. Liver Transpl 2012;18:188–94.
[45] Mills RE, Taylor KR, Podshivalova K, McKay DB, Jameson JM. Defects in skin γδ T
cell function contribute to delayed wound repair in rapamycin-treated mice.
J Immunol 2008;181:3974–83.
[46] Squarize CH, Castilho RM, Bugge TH, Gutkind JS. Accelerated wound healing by
mTOR activation in genetically deﬁned mouse models. PLoS One 2010;5:e10643.
[47] Røine E, Bjørk IT, Øyen O. Targeting risk factors for impaired wound healing and
wound complications after kidney transplantation. Transplant Proc 2010;42:2542–6.
[48] Stallone G, Infante B, Grandaliano G, Gesualdo L. Management of side effects of
sirolimus therapy. Transplantation 2009;87:S23–6.
[49] Manito N, Delgado JF, Crespo-Leiro MG, et al. Clinical recommendations for
the use of everolimus in heart transplantation. Transplant Rev (Orlando)
2010;24:129–42.
[50] Derweesh IH, Ismail HR, Goldfarb DA, et al. Intraoperative placing of drains
decreases the incidence of lymphocele and deep vein thrombosis after renal
transplantation. BJU Int 2008;101:1415–9.
[51] Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert
Opin Drug Saf 2013;12:177–86.
133B. Kaplan et al. / Transplantation Reviews 28 (2014) 126–133[52] Kennealey PT, Johnson CS, Tector III AJ, Selzer DJ. Laparoscopic incisional hernia
repair after solid-organ transplantation. Arch Surg 2009;144:228–33.
[53] Harth KC, Broome AM, Jacobs MR, et al. Bacterial clearance of biologic grafts used
in hernia repair: an experimental study. Surg Endosc 2011;25:2224–9.
[54] BrewerMB, Rada EM, MilburnML, et al. Human acellular dermalmatrix for ventral
hernia repair reduces morbidity in transplant patients. Hernia 2011;15:141–5.
[55] Desai N, Heenan S, Mortimer PS. Sirolimus-associated lymphoedema: eight new
cases and a proposed mechanism. Br J Dermatol 2009;160:1322–6.
[56] Cosio FG, Hickson LJ, Grifﬁn MD, Stegall MD, Kudva Y. Patient survival and
cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J
Transplant 2008;8:593–9.
[57] Vincenti F, Friman S, Scheuermann E, et al. Results of an international,
randomized trial comparing glucose metabolism disorders and outcome with
cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506–14.
[58] Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus.
J Endocrinol Invest 2000;23:482–90.
[59] Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset
diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411–8.
[60] Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in
renal transplant recipients: 6-month safety and efﬁcacy results of two
randomized studies. Am J Transplant 2004;4:626–35.
[61] Krämer BK, Neumayer HH, Stahl R, et al. Graft function, cardiovascular risk factors,
and sexhormones in renal transplant recipients onan immunosuppressive regimen
of everolimus, reduced dose of cyclosporine, and basiliximab. Transplant Proc
2005;37:1601–4.
[62] Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin
prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state
in type 2 diabetes. Diabetes 2008;57:945–57.
[63] Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects
associated with anticancer agents targeting the PI3K–Akt–mTOR pathway. J Clin
Oncol 2012;30:2919–28.
[64] Gerullis H, Bergmann L, Maute L, Eimer C, Otto T. Experiences and practical
conclusions concerning temsirolimus use and adverse event management in
advanced renal cell carcinoma within a compassionate use program in Germany.
Cancer Chemother Pharmacol 2009;63:1097–102.
[65] Rodriguez-Pascual J, Cheng E, Maroto P, Duran I. Emergent toxicities associated
with the use of mTOR inhibitors in patients with advanced renal carcinoma.
Anticancer Drugs 2010;21:478–86.
[66] Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type
2 diabetes: a patient-centered approach: position statement of the American
Diabetes Association (ADA) and the European Association for the Study of
Diabetes (EASD). Diabetes Care 2012;35:1364–79.
[67] Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R.
Comparison of sirolimus and everolimus in their effects on blood lipid proﬁles
and haematological parameters in heart transplant recipients. Clin Transplant
2007;21:536–43.
[68] National Cholesterol Education Program. Available at http://www.nhlbi.nih.gov/
about/ncep/ . [Accessed June 14, 2013].
[69] Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing
dyslipidemias in kidney transplant patients: a report from the Managing
Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant
2004;4:13–53.
[70] Knoll GA. Proteinuria in kidney transplant recipients: prevalence, prognosis, and
evidence-based management. Am J Kidney Dis 2009;54:1131–44.
[71] Suárez Fernández ML, Cosio F. Causes and consequences of proteinuria following
kidney transplantation. Nefrologia 2011;31:404–14.
[72] Arnau A, Ruiz JC, Rodrigo E, Quintanar JA, Arias M. Is proteinuria reversible, after
withdrawal of mammalian target of rapamycin inhibitors? Transplant Proc
2011;43:2194–5.
[73] Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms,
signiﬁcance, and management. Transplant Rev (Orlando) 2008;22:125–30.
[74] Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and
graft function in de novo sirolimus-based vs. calcineurin inhibitor-based
immunosuppression in live donor kidney transplantation. Transplantation
2006;82:368–74.
[75] KirschAH,RiegelbauerV, TagwerkerA, RudnickiM,RosenkranzAR,EllerK. ThemTOR-
inhibitor rapamycinmediatesproteinuria innephrotoxic serumnephritis byactivating
the innate immune response. Am J Physiol Renal Physiol 2012;303:F569–75.
[76] Diekmann F, Andres A, Oppenheimer F. mTOR inhibitor-associated proteinuria in
kidney transplant recipients. Transplant Rev (Orlando) 2012;26:27–9.
[77] Stallone G, Infante B, Pontrelli P, et al. Sirolimus and proteinuria in renal
transplant patients: evidence for a dose-dependent effect on slit diaphragm-
associated proteins. Transplantation 2011;91:997–1004.
[78] Klawitter J, Bendrick-Peart J, Rudolph B, et al. Urine metabolites reﬂect time-
dependent effects of cyclosporine and sirolimus on rat kidney function. Chem
Res Toxicol 2009;22:118–28.
[79] Bohra R, Schöning W, Klawitter J, et al. Everolimus and sirolimus in combination
with cyclosporine have different effects on renal metabolism in the rat. PLoS One
2012;7:e48063.[80] Holdaas H, Midtvedt K, Asberg A. A drug safety evaluation of everolimus in
kidney transplantation. Expert Opin Drug Saf 2012;11:1013–22.
[81] Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of
cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation
1996;62:311–6.
[82] Christians U, Gottschalk S, Miljus J, et al. Alterations in glucose metabolism by
cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR
inhibitors. Br J Pharmacol 2004;143:388–96.
[83] Kaplan B, Tedesco-Silva H, Mendez R, et al. North/South American, double-blind,
parallel group study of the safety and efﬁcacy of Certican™ (RAD) versus
mycophenolatemofetil (MMF) in combination with Neoral® and corticosteroids.
Am J Transplant 2001;1:475-475 [Abstract 1339].
[84] Shihab FS, Cibrik D, Chan L, et al. Association of clinical events with everolimus
exposure in kidney transplant patients receiving reduced cyclosporine. Clin
Transplant 2013;27:217–26.
[85] McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from
delayed graft function after cadaveric renal transplantation. Am J Transplant
2003;3:416–23.
[86] Nogueira JM, Haririan A, Jacobs SC, et al. The detrimental effect of poor early graft
function after laparoscopic live donor nephrectomy on graft outcomes. Am J
Transplant 2009;9:337–47.
[87] Dantal J, Berthoux F, Moal MC, et al. Efﬁcacy and safety of de novo or early
everolimus with low cyclosporine in deceased-donor kidney transplant
recipients at speciﬁed risk of delayed graft function: 12-month results of a
randomized, multicenter trial. Transpl Int 2010;23:1084–93.
[88] Lieberthal W, Levine JS. Mammalian target of rapamycin and the kidney. II.
Pathophysiology and therapeutic implications. Am J Physiol Renal Physiol
2012;303:F180–91.
[89] White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus
therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med
2010;182:396–403.
[90] Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary
toxicity. Transplantation 2004;77:1215–20.
[91] Feagans J, Victor D, Moehlen M, et al. Interstitial pneumonitis in the transplant
patient: consider sirolimus-associated pulmonary toxicity. J La State Med Soc
2009;161:166–72.
[92] Alexandru S, Ortiz A, Baldovi S, et al. Severe everolimus-associated pneumonitis
in a renal transplant recipient. Nephrol Dial Transplant 2008;23:3353–5.
[93] Filippone EJ, Carson JM, Beckford RA, et al. Sirolimus-induced pneumonitis
complicated by pentamidine-induced phospholipidosis in a renal transplant
recipient: a case report. Transplant Proc 2011;43:2792–7.
[94] Fishbane S, Cohen DJ, Coyne DW, Djamali A, Singh AK, Wish JB. Posttransplant
anemia: the role of sirolimus. Kidney Int 2009;76:376–82.
[95] Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Barrientos A. Study of
anemia after late introduction of everolimus in the immunosuppressive
treatment of renal transplant patients. Transplant Proc 2007;39:2242–4.
[96] McDonald MA, Gustafsson F, Almasood A, Barth D, Ross HJ. Sirolimus is
associated with impaired hematopoiesis in heart transplant patients? A
retrospective analysis. Transplant Proc 2010;42:2693–6.
[97] Fernández Fresnedo G, Palomar R, Rodrigo E, et al. Prevalence of anemia in renal
transplant patients: results from MOST, an observational trial. Transplant Proc
2005;37:3821–2.
[98] Diekmann F, Rovira J, Diaz-Ricart M, et al. mTOR inhibition and erythropoiesis:
microcytosis or anaemia? Nephrol Dial Transplant 2012;27:537–41.
[99] Jacobson PA, Schladt D, OettingWS, et al. Genetic determinants of mycophenolate-
related anemia and leukopenia after transplantation. Transplantation
2011;91:309–16.
[100] Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in
renal transplant recipients: risk factors, incidence, progression, and manage-
ment. Transplantation 2000;69:2085–90.
[101] Zeier M, van der Giet M. Calcineurin inhibitor sparing regimens using m-target of
rapamycin inhibitors: an opportunity to improve cardiovascular risk following
kidney transplantation? Transpl Int 2011;24:30–42.
[102] Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K. Increased
incidence of angioedema with ACE inhibitors in combination with mTOR
inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010;5:703–8.
[103] Rovira J, Diekmann F, Ramírez-Bajo MJ, Bañón-Maneus E, Moya-Rull D, Campistol
JM. Sirolimus-associated testicular toxicity: detrimental but reversible. Trans-
plantation 2012;93:874–9.
[104] Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH.
Testosterone concentrations and sirolimus in male renal transplant patients.
Am J Transplant 2004;4:130–1.
[105] Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L. Gonadal impact of target
of rapamycin inhibitors (sirolimus and everolimus) in male patients: an
overview. Transpl Int 2007;20:305–11.
[106] Alfadhli E, Koh A, Albaker W, et al. High prevalence of ovarian cysts in
premenopausal women receiving sirolimus and tacrolimus after clinical islet
transplantation. Transpl Int 2009;22:622–5.
[107] Cure P, Pileggi A, Froud T, et al. Alterations of the female reproductive system in
recipients of islet grafts. Transplantation 2004;78:1576–81.
